Biopharma Competition Healthcare Provider Pharma 
Impetus Digital
MARCH 15, 2024
Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). There are currently more than 2,000 oncology products under development.
PM360
APRIL 22, 2024
With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
AUGUST 9, 2022
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.
Clarivate
APRIL 24, 2023
After Walgreens upped its ownership stake in the primary-care company VillageMD from 30 to 63 percent and then announced plans to operate 1,000 clinics by 2027, the writing was on the wall: to stay competitive and manage costs in CVS’ newly integrated Aetna plan, CVS could benefit by making a larger bid for primary care of its own.
Clarivate
APRIL 18, 2024
Signify’s healthcare platform also assists 65,000 provider partners to participate in value-based care with nearly 1 million attributed lives Oak Street Health acquisition May 2023 CVS acquired Oak Street for $10.6 As of January 2024, CVS reported the number of Aetna members being treated by Oak Street had doubled.
Expert insights. Personalized for you.
78 
Let's personalize your content